8049 Stock Overview
Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Jilin Province Huinan Changlong Bio-pharmacy Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.85 |
| 52 Week High | HK$2.05 |
| 52 Week Low | HK$1.07 |
| Beta | 0.13 |
| 1 Month Change | -5.13% |
| 3 Month Change | 12.12% |
| 1 Year Change | 6.94% |
| 3 Year Change | 48.00% |
| 5 Year Change | 54.17% |
| Change since IPO | 33.09% |
Recent News & Updates
There May Be Reason For Hope In Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) Disappointing Earnings
Apr 04
With EPS Growth And More, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Makes An Interesting Case
Mar 26Investors Don't See Light At End Of Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Tunnel
Dec 27Recent updates
There May Be Reason For Hope In Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) Disappointing Earnings
Apr 04With EPS Growth And More, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Makes An Interesting Case
Mar 26Investors Don't See Light At End Of Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Tunnel
Dec 27With EPS Growth And More, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Makes An Interesting Case
Jul 12It's Unlikely That Shareholders Will Increase Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Compensation By Much This Year
Jun 05How Is Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) CEO Paid Relative To Peers?
Nov 26Shareholder Returns
| 8049 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 8.2% | -4.5% | -2.0% |
| 1Y | 6.9% | -21.8% | -14.3% |
Return vs Industry: 8049 exceeded the Hong Kong Pharmaceuticals industry which returned -21.9% over the past year.
Return vs Market: 8049 exceeded the Hong Kong Market which returned -15% over the past year.
Price Volatility
| 8049 volatility | |
|---|---|
| 8049 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 8049 has not had significant price volatility in the past 3 months.
Volatility Over Time: 8049's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 848 | Hong Zhang | www.jlchanglong.com |
Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People’s Republic of China. It offers Edaravone injection, compound brain comfort capsules, haikun kidney hi capsules, cefpirome sulfate for injections, Cefpiramide for injections, anti-bone hyperplasia tablets, Lysine glucosa tablets, prostate laurel yellow tablets, tranquility tablets, pharyngitis tablets, and low back pain capsules. The company markets its products under the Changlong and Qing Tong brands.
Jilin Province Huinan Changlong Bio-pharmacy Company Limited Fundamentals Summary
| 8049 fundamental statistics | |
|---|---|
| Market cap | HK$1.04b |
| Earnings (TTM) | HK$160.36m |
| Revenue (TTM) | HK$910.54m |
6.5x
P/E Ratio1.1x
P/S RatioIs 8049 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8049 income statement (TTM) | |
|---|---|
| Revenue | CN¥841.55m |
| Cost of Revenue | CN¥257.50m |
| Gross Profit | CN¥584.05m |
| Other Expenses | CN¥435.84m |
| Earnings | CN¥148.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.26 |
| Gross Margin | 69.40% |
| Net Profit Margin | 17.61% |
| Debt/Equity Ratio | 5.4% |
How did 8049 perform over the long term?
See historical performance and comparison